# Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases

> **NCT06023173** · — · COMPLETED · sponsor: **Fudan University** · enrollment: 307 (actual)

## Conditions studied

- The Patients With CRLM Who Benefit More From Bevacizumab

## Interventions

- **DIAGNOSTIC_TEST:** Deep radiomics-based fusion model

## Key facts

- **NCT ID:** NCT06023173
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10-01
- **Primary completion:** 2023-01-01
- **Final completion:** 2023-01-01
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2023-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06023173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06023173, "Deep Radiomics-based Fusion Model Predicting Bevacizumab Treatment Response and Outcome in Patients With Colorectal Liver Metastases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06023173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*